TCTMD

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
The New England Journal of Medicine

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

In patients with heart failure with preserved ejection fraction and obesity, semaglutide (2.4 mg) led to greater reductions in symptoms and physical limitations and greater improvements in exercise ...
The New England Journal of Medicine

Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction

The therapeutic efficacy of the cardiac glycoside digitoxin in patients with heart failure and reduced ejection fraction is not established. In this international, double-blind, placebo-controlled ...
Nasdaq

Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction

SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation of ...